ライフサイエンスコーパス: congestive heart failure

1 med angina, silent MI, revascularization, or congestive heart failure).

2 resistance and severe cardiotoxicity (e.g., congestive heart failure).

3 adverse events (grade 2 fatigue and grade 4 congestive heart failure).

4 potension, bradycardia, bronchospasm, and/or congestive heart failure).

5 were male; 13% had had a stroke; and 45% had congestive heart failure.

6 Captopril, which is generally used to treat congestive heart failure.

7 ute myocardial infarction and for those with congestive heart failure.

8 nary artery disease, arrhythmias, stroke, or congestive heart failure.

9 prevention of DOX-induced cardiotoxicity and congestive heart failure.

10 ent with pacemaker syndrome, and 1 developed congestive heart failure.

11 ass index, ejection fraction, and history of congestive heart failure.

12 ation are at an increased risk of developing congestive heart failure.

13 tant tool for the diagnosis and treatment of congestive heart failure.

14 chexia is a life threatening complication in congestive heart failure.

15 icrobial diversity and richness in dogs with congestive heart failure.

16 ated to the chronic conditions of asthma and congestive heart failure.

17 k between the abdomen, heart, and kidneys in congestive heart failure.

18 rdiomyopathies, which are a leading cause of congestive heart failure.

19 ilure was noted for patients with underlying congestive heart failure.

20 lications, such as myocardial infarction and congestive heart failure.

21 seases, such as ventricular fibrillation and congestive heart failure.

22 prematurity, sleep disordered breathing and congestive heart failure.

23 s required in 23 patients, mainly because of congestive heart failure.

24 al fibrillation, ischemic heart diseases, or congestive heart failure.

25 e consisting of death, reinfarction, and new congestive heart failure.

26 of grade 3 neuropathy, and 2 had symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), bot

27 ; HR: 1.18; 95% CI: 1.04 to 1.34; p = 0.01), congestive heart failure (107 events; HR: 1.25; 95% CI:

28 ), coronary artery disease (34% versus 32%), congestive heart failure (19% versus 15%), and diabetes

29 6-3.69), high-risk surgery 2.70 (2.46-2.96), congestive heart failure 2.65 (2.29-3.06), cerebrovascul

30 lized for acute myocardial infarction (19%), congestive heart failure (25%), pneumonia (30%), and con

31 04), stroke (2.43% vs. 1.93%; p = 0.05), and congestive heart failure (3.75% vs. 2.25%; p < 0.0001) t

32 7.4 years; P = .035) and more likely to have congestive heart failure (35.3% vs 24.5%; P < .001) and

33 ents, and the most common cause of death was congestive heart failure (37%).

34 -20.4%), cardiac dysrhythmias (21.7%-29.0%), congestive heart failure (40.7%-56.1%), acute (5.9%-20.1

35 r dysfunction, but blacks had more prevalent congestive heart failure (43% versus 34%; P=0.04) and le

36 ry disease (26.6 to 12.6% of admissions) and congestive heart failure (8.5 to 5.4% of admissions).

37 n particular, SGLT2 inhibitors lower risk of congestive heart failure, a major cardiovascular complic

38 ascular events, and disease-specific events: congestive heart failure, acute myocardial infarction, a

39 disease, ascites, sepsis, smoking, steroid, congestive heart failure, acute renal failure, and dyspn

40 OR: 0.36; 95% CI: 0.31 to 0.42; p < 0.001), congestive heart failure (adjusted OR: 0.82; 95% CI: 0.7

41 A composite outcome of death and congestive heart failure admission was recorded.

42 et the composite end point (48 deaths and 19 congestive heart failure admissions, 2.5% 30-day deaths)

43 s were more likely to have had AKI, multiple congestive heart failure admissions, and other hospitali

44 revention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarcti

45 were to identify correlates of mortality and congestive heart failure after aortic valve replacement

46 relates of the composite outcome of death or congestive heart failure after AVR.

47 rate of major adverse cardiac events and new congestive heart failure after ST-segment-elevation myoc

48 ncidence of coronary artery disease, stroke, congestive heart failure, all-cause mortality, and cardi

49 s ago, are used to treat hypertension and/or congestive heart failure, although there are therapeutic

50 vent (heart attack, stroke, new or worsening congestive heart failure, amputation for ischemic gangre

51 nfarction, nonfatal stroke, new or worsening congestive heart failure, amputation for ischemic gangre

52 to the emergency department with symptoms of congestive heart failure and a 1-week history of chest p

53 Dilated cardiomyopathy is a leading cause of congestive heart failure and a debilitating complication

54 radation of cardiac control in patients with congestive heart failure and a more degradation in criti

55 ing hospitalization for sepsis compared with congestive heart failure and acute myocardial infarction

56 readmissions following sepsis compared with congestive heart failure and acute myocardial infarction

57 ative to other high-risk conditions, such as congestive heart failure and acute myocardial infarction

58 on diagnoses at the time of readmission were congestive heart failure and arrhythmia.

59 high rates of readmission, predominantly for congestive heart failure and arrhythmia.

60 of left ventricular failure in patients with congestive heart failure and bronchoconstriction.

61 arison of Surgical and Medical Treatment for Congestive Heart Failure and Coronary Artery Disease [ST

62 re embryonic day 9; TnT/Isl1-Cre) results in congestive heart failure and death by embryonic day 11.5

63 left ventricular (LV) decline, resulting in congestive heart failure and death.

64 g dialysis patients, warfarin users had more congestive heart failure and diabetes mellitus, but fewe

65 also compared for patients with a history of congestive heart failure and for patients aged >/=80.

66 requent; however, exacerbation of asthma and congestive heart failure and one fatal cerebral hemorrha

67 admitted to our hospital with decompensated congestive heart failure and pericardial effusion diagno

68 t Failure Score, ESCAPE [Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

69 portions of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

70 and (2) patients in the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheteriz

71 In phase 3, 19 patients with congestive heart failure and pulmonary hypertension cons

72 ase 2, 32 participants (including those with congestive heart failure and pulmonary hypertension) use

73 ment of the pathophysiology of congestion in congestive heart failure and the methods by which we det

74 0 million/yr for sepsis, $229 million/yr for congestive heart failure, and $142 million/yr for acute

75 22.9%; interquartile range, 19.2-26.6%) for congestive heart failure, and 3.6% to 40.8% (median, 17.

76 tes were 20.4%, 23.6%, and 17.7% for sepsis, congestive heart failure, and acute myocardial infarctio

77 outcomes were myocardial infarction, stroke, congestive heart failure, and cardiovascular mortality.

78 ey role in the pathogenesis of hypertension, congestive heart failure, and chronic kidney disease.

79 osterone synthase) can lead to hypertension, congestive heart failure, and diabetic nephropathy.

80 Older age, congestive heart failure, and greater left ventricular d

81 age, sex, race, diabetes status, presence of congestive heart failure, and hemoglobin, serum albumin,

82 l history included diabetes mellitus type 2, congestive heart failure, and hypertension.

83 FDCM and IDCM but for both groups older age, congestive heart failure, and increased left ventricular

84 ng age, male gender, pulmonary hypertension, congestive heart failure, and liver disease are risk fac

85 Procedural complications, congestive heart failure, and low hospital AF ablation v

86 composite primary end point of death, shock, congestive heart failure, and reinfarction when compared

87 increased risk for death, cardiac death, and congestive heart failure, and subjects presenting PTF >/

88 strongly influenced by severe liver disease, congestive heart failure, and weight, factors that shoul

89 er secondary events including hip fractures, congestive heart failure, angina, falls, depression, cho

90 le gender (aOR, 1.61; 95% CI, 1.42 to 1.84), congestive heart failure (aOR, 1.20; 95% CI, 1.03 to 1.3

91 % confidence interval [CI]: 157.7 to 238.0), congestive heart failure (aOR: 49.1; 95% CI: 37.4 to 64.

92 (age >65 [aOR 3.0, 95%CI 1.7-5.5, p<0.001], congestive heart failure [aOR 3.2, 95%CI 1.4-7.0, p=0.00

93 V outcomes including coronary heart disease, congestive heart failure, arrhythmias, and stroke.

94 re likely to have had a primary diagnosis of congestive heart failure at the time of index admission,

95 pitalized for acute myocardial infarction or congestive heart failure but not among those hospitalize

96 , chronic obstructive pulmonary disease, and congestive heart failure) by using the Cox proportional

97 The primary composite was all-cause death, congestive heart failure, cardiogenic shock, and recurre

98 he in-hospital composite end point of death, congestive heart failure, cardiogenic shock, and reinfar

99 older and were more likely to have comorbid congestive heart failure, cardiomyopathy, cerebrovascula

100 f acute myocardial infarction cases, 1.7% of congestive heart failure cases, and 5.8% of stroke cases

101 adjusted odds ratio [aOR]: 4.06; p < 0.001), congestive heart failure (CHF) (aOR: 2.20; p = 0.011) an

102 e to UFPs and nitrogen dioxide with incident congestive heart failure (CHF) and acute myocardial infa

103 associated with greater risk of adjudicated congestive heart failure (CHF) and atherosclerotic event

104 mplication of many chronic diseases, such as congestive heart failure (CHF) and chronic kidney diseas

105 Secondary analyses assessed incident congestive heart failure (CHF) and mortality with coexis

106 Patients with congestive heart failure (CHF) have impaired functional

107 Congestive heart failure (CHF) is a leading cause of mor

108 uch as acute myocardial infarction (AMI) and congestive heart failure (CHF) is inconclusive, especial

109 Patients with advanced congestive heart failure (CHF) or chronic kidney disease

110 Patients with advanced congestive heart failure (CHF) or chronic kidney disease

111 valence of mental stress-induced ischemia in congestive heart failure (CHF) patients is unknown.

112 HIV-infected individuals have excess congestive heart failure (CHF) risk compared with uninfe

113 -myocardial infarction use of beta-blockers; congestive heart failure (CHF) with use of angiotensin-c

114 Cardiac death, severe congestive heart failure (CHF), and confirmed significan

115 termine hazard ratios (HR) for incident CHD, congestive heart failure (CHF), and other causes of deat

116 admissions for ischemic heart disease (IHD), congestive heart failure (CHF), and overall CVD were obt

117 In congestive heart failure (CHF), carotid body (CB) chemor

118 echolamine stimulation during development of congestive heart failure (CHF), chronic activation of Gs

119 ulation-level influenza rates in adults with congestive heart failure (CHF), coronary artery disease

120 ital arrhythmias, eclampsia or preeclampsia, congestive heart failure (CHF), length of stay, preterm

121 m from cardiology, neurology and psychiatry: Congestive Heart Failure (CHF), Major Depression Disorde

122 patients without cirrhosis and patients with congestive heart failure (CHF), matched for age, sex, an

123 rate to severe chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease

124 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether

125 tions for acute myocardial infarction (AMI), congestive heart failure (CHF), or pneumonia and whether

126 hospitalization or emergency room visit for congestive heart failure (CHF), outpatient diagnosis of

127 on (MI), other ischemic heart disease (IHD), congestive heart failure (CHF), stroke, chronic kidney d

128 ions (PVCs) are a modifiable risk factor for congestive heart failure (CHF).

129 ation), Kussmaul sign, has been described in congestive heart failure (CHF).

130 n-ischemic cardiomyopathy without history of congestive heart failure (CHF).

131 ork learning of chest radiograph features in congestive heart failure (CHF).

132 uracy for chest radiography in patients with congestive heart failure (CHF).

133 lation (AF), myocardial infarction (MI), and congestive heart failure (CHF).

134 percent of clopidogrel-treated patients with congestive heart failure, cholecystectomy, and lower per

135 scular disease, peripheral vascular disease, congestive heart failure, chronic obstructive pulmonary

136 PE that had no corresponding comorbidities, congestive heart failure, chronic pulmonary disease, coa

137 has grown to include chronic kidney disease, congestive heart failure, chronic pulmonary diseases, an

138 ary outcomes were hospitalization because of congestive heart failure, coronary heart disease, new on

139 um concentrations, as occur in patients with congestive heart failure, could activate the PKD1/HDAC5/

140 ardiac arrhythmias, coronary artery disease, congestive heart failure, diabetes mellitus, and stroke

141 rior stroke, older age, atrial fibrillation, congestive heart failure, diabetes mellitus, myocardial

142 One patient with congestive heart failure died from refractory left ventr

143 cute coronary syndrome, atrial fibrillation, congestive heart failure, DM 2, and smoking.

144 A total of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchron

145 atal myocardial infarction, unstable angina, congestive heart failure, emergency coronary revasculari

146 In CHS, 997 congestive heart failure events occurred during 39 238 p

147 ing 39 238 person-years; in ARIC, 330 events congestive heart failure events occurred during 64 438 p

148 = 4; 13.8%), unstable angina (n = 8; 27.6%), congestive heart failure exacerbations (n = 4; 13.8%), e

149 Multivariate analysis showed that congestive heart failure greater than or equal to New Yo

150 crease in abundance of Proteobacteria in the congestive heart failure group (p = 0.014), particularly

151 0-day death or combined endpoint (defined as congestive heart failure >/= New York Heart Association

152 The top hospital quartile of ICU use for congestive heart failure had a sensitivity of 50-60% and

153 sympathetic overstimulation in patients with congestive heart failure have a negative inotropic effec

154 We conclude that dogs with congestive heart failure have dysbiosis, and we show add

155 About one-half of the patients with congestive heart failure have preserved left ventricular

156 We hypothesised that dogs with congestive heart failure have quantifiable dysbiosis com

157 earts and paroxysmal AF, although those with congestive heart failure have the greatest potential ben

158 erent comorbidities (diabetes, hypertension, congestive heart failure, hemodialysis-dependence, cance

159 astolic dysfunction without the diagnosis of congestive heart failure (HF) and with normal systolic f

160 event the rare, but serious, complication of congestive heart failure (HF) associated with anthracycl

161 .05-1.44), thromboembolism 1.32 (1.17-1.49), congestive heart failure HR 1.57 (1.39-1.78), depression

162 litus (HR, 1.42; 95% CI, 1.01-2.00; P=0.04), congestive heart failure (HR, 1.88; 95% CI, 1.12-3.16; P

163 6; 95% confidence interval [CI], 1.80-3.11), congestive heart failure (HR, 2.16; 95% CI, 1.70-2.72),

164 .1 +/- 8.1 years, the mean CHA(2)DS(2)-VASc (congestive heart failure, hypertension, 65 years of age

165 o clinical risk factors and the CHA2DS2VASc (congestive heart failure, hypertension, 75 years of age

166 Clinical schemas, such as the CHA2DS2-VASc (congestive heart failure, hypertension, age >/= 75 years

167 Median CHADS2 score (congestive heart failure, hypertension, age >/= 75 years

168 CHA2DS2VASc scores (congestive heart failure, hypertension, age >/=75 years

169 The CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 years

170 er PVI in association with the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years

171 After adjustment for the CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 years

172 African-American ethnicity to CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

173 oint on the stroke risk scheme CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

174 sk patients, i.e., with 0 or 1 CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75 years,

175 ith atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >/=75 years,

176 nd bleeding risks were assessed by using the congestive heart failure, hypertension, age >/=75 years,

177 over established risk stratification scores (congestive heart failure, hypertension, age >/=75 years,

178 ears, diabetes, previous stroke [CHADS2] and congestive heart failure, hypertension, age >/=75 years,

179 sk factors, as measured by the CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe

180 h atrial fibrillation (AF) with a "low-risk" congestive heart failure, hypertension, age >/=75, diabe

181 erformance of ATRIA to that of CHA2DS2-VASc (congestive heart failure, hypertension, age >/=75, diabe

182 Patients with NVAF who had a CHADS2 (congestive heart failure, hypertension, age >75 years, d

183 y mass index (BMI); and have a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age >= 75 years,

184 antly older and had higher CHA(2)DS(2)-VASc (congestive heart failure, hypertension, age >=75 years,

185 in CHA2DS2-VASc score (a risk score based on congestive heart failure, hypertension, age 75 years or

186 Although the CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or

187 e in subjects with ESVEA and a CHA2DS2-VASc (congestive heart failure, hypertension, age 75 years or

188 s had atrial fibrillation, CHA(2)DS(2)-VASc (Congestive heart failure, Hypertension, Age 75 years, Di

189 average age of 70+/-12 years, a mean CHADS2 (congestive heart failure, hypertension, age>75, diabetes

190 alvular atrial fibrillation (AF) and CHADS2 (congestive heart failure, hypertension, age, diabetes me

191 with severe cardiovascular diseases such as congestive heart failure, hypertension, and myocardial f

192 Among AF patients, age >/=75 years, congestive heart failure, hypertension, diabetes mellitu

193 risk factors (diabetes mellitus, history of congestive heart failure, hypertension, or age older tha

194 ted in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic neph

195 ted with CKD in individual CHA(2)DS(2)-VASc (Congestive heart failure; Hypertension; Age >/=75 years;

196 etary sources, were associated with incident congestive heart failure in 2 independent cohorts, sugge

197 ession of, for instance, sleep disorders and congestive heart failure in diabetic patients.

198 ac events at 90 days with significantly less congestive heart failure in the intracoronary abciximab

199 riven by a significantly reduced rate of new congestive heart failure in the RIC and PostC group (2.7

200 of chronic obstructive pulmonary disease or congestive heart failure in univariate analyses.

201 ting as asymptomatic cardiac dysfunction and congestive heart failure in up to 57% and 16% of patient

202 Two hundred and four (6.9%) patients had new congestive heart failure (incidence, 38.42/1000 patient-

203 Here, in the International Congestive Heart Failure (INTER-CHF) study, we aimed to

204 Congestive heart failure is a major cause of morbidity,

205 Congestive heart failure is characterized by suppressed

206 Congestive heart failure is one of the leading causes of

207 relatively early stages, the abrupt onset of congestive heart failure is uncommon and should raise su

208 In this population, congestive heart failure is well recognised as a progres

209 patients with cardiovascular disease such as congestive heart failure, ischemic heart disease, valvul

210 -eluting stent; 2 points each for history of congestive heart failure/low ejection fraction and vein

211 included young age, low weight, presence of congestive heart failure, lower left ventricular fractio

212 was a composite of death, re-infarction, and congestive heart failure (major adverse cardiac events [

213 nate disease, cardiomyopathy with or without congestive heart failure, megaviscera, and death.

214 l in which weight, severe liver disease, and congestive heart failure most affected fentanyl concentr

215 he primary safety endpoint were age, anemia, congestive heart failure, multivessel disease, number of

216 ac respiratory failure, atrial fibrillation, congestive heart failure, myocardial infarction, and reo

217 ard Medical Therapy in Elderly Patients With Congestive Heart Failure; n=431), and HF-ACTION trial (H

218 mprove Clinical Outcomes in Individuals With Congestive Heart Failure; NCT00047437).

219 tient with a history of atrial fibrillation, congestive heart failure (NYHA II/III), stable coronary

220 sease (odds ratio, 1.22; 95% CI, 1.11-1.34), congestive heart failure (odds ratio, 1.14; 95% CI, 1.08

221 cardiac end point was defined as symptomatic congestive heart failure of New York Heart Association c

222 Conclusion Features of congestive heart failure on chest radiographs learned by

223 ction, stroke, gastrointestinal bleeding, or congestive heart failure or a Diagnosis Related Group cl

224 ac death or arrest, ventricular arrhythmias, congestive heart failure or arrhythmias requiring admiss

225 thin the categories of sudden death, cancer, congestive heart failure or chronic lung disease, and fr

226 in patients with mild to moderate anemia and congestive heart failure or coronary heart disease.

227 The risk of new MI, being admitted with congestive heart failure or death, increased with increa

228 ization was more pronounced in patients with congestive heart failure or ischemic heart disease than

229 Among high-risk subjects, those with congestive heart failure or ischemic stroke as their ind

230 nts with AA were older, presented with acute congestive heart failure or non-ST-segment-elevation myo

231 Patients with congestive heart failure or reduced left ventricular eje

232 e in the previous 6 months or who had severe congestive heart failure or severe renal impairment were

233 reast cancer, except for those with clinical congestive heart failure or significantly compromised le

234 tion (OR 1.97; 95% CI 1.64-2.35; p < 0.001), congestive heart failure (OR 1.42; 95% CI 1.21-1.67; p <

235 llation (OR, 0.82; CI, 0.70-0.95; P = 0.01), congestive heart failure (OR, 0.73; CI, 0.60-0.88; P < 0

236 22; 95% CI, 1.00-1.48; P = .045), history of congestive heart failure (OR, 1.25; 95% CI, 1.12-1.39; P

237 liver disease (OR, 1.57; 95% CI, 1.39-1.77); congestive heart failure (OR, 1.49; 95% CI, 1.38-1.61);

238 Congestive heart failure (OR, 1.7; 95% CI, 1.3-2.2), car

239 Patients with preexisting diabetes mellitus, congestive heart failure, or chronic or acute renal fail

240 infarction, acute coronary syndrome, stroke, congestive heart failure, or CVD death), and (ii) seriou

241 eficiaries with acute myocardial infarction, congestive heart failure, or pneumonia, 30-day mortality

242 y revascularisation, hospital admission with congestive heart failure, or stroke, which was assessed

243 ent CVD manifestations such as heart attack, congestive heart failure, or stroke.

244 rmed HCM presented with rapid development of congestive heart failure over 6 months, in sharp contras

245 (P </= 0.04), heart attack (P </= 0.01), and congestive heart failure (P </= 0.02), but not with stro

246 P<0.001), pulmonary hypertension (P<0.0001), congestive heart failure (P=0.0008), and liver disease (

247 Congestive heart failure, paraplegia, dyspnea at rest, a

248 contained 10 categorical variables including congestive heart failure, paraplegia, reoperation, dyspn

249 One new serious adverse event suggestive of congestive heart failure (pertuzumab group) and one new

250 comitant treatment with SS31 ameliorated the congestive heart failure phenotypes and mitochondrial da

251 05 and 2011 for acute myocardial infarction, congestive heart failure, pneumonia, or conditions requi

252 ese steps using a hypothetical example for a congestive heart failure postdischarge clinic.

253 History of congestive heart failure predicted midodrine continuatio

254 gnosis at index AKI hospitalization included congestive heart failure (primary diagnosis), decompensa

255 dial infarction, stroke, hospitalization for congestive heart failure, progressive renal insufficienc

256 ard Medical therapy in Elderly patients with Congestive Heart Failure randomized 499 patients with HF

257 er the inclusion of an SES measure in 30-day congestive heart failure readmission models changed hosp

258 y mass index, noncardiac surgery, history of congestive heart failure, renal disease, existing airway

259 t disease (RR, 4.31; 95% CI, 3.38-5.49), and congestive heart failure (RR, 2.05; 95% CI, 1.29-3.25).

260 Evaluate Challenging Responses to Therapy in Congestive Heart Failure (SECRET of CHF) trials.

261 de prostate and breast cancers, uncontrolled congestive heart failure, severe lower-urinary-tract sym

262 nute walk test (6MWT) independently predicts congestive heart failure severity, death, and heart fail

263 us thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered breathing, ga

264 -salt diet, a model for hypertension-induced congestive heart failure, spermidine feeding reduced sys

265 llowed them for 2 years to assess mortality, congestive heart failure, stroke or transient ischemic a

266 s also been linked to myocardial infarction, congestive heart failure, stroke, and diabetes mellitus

267 al infarction, coronary heart disease death, congestive heart failure, stroke, incident angina, or in

268 A composite of CVD events defined as congestive heart failure, stroke, or myocardial infarcti

269 ical diagnoses (acute myocardial infarction, congestive heart failure, stroke, pneumonia, and chronic

270 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure Study (TACTICS) and Study to Ev

271 Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure) study was conducted to address

272 A multivariable model-including angina, congestive heart failure symptoms, shockable arrest rhyt

273 Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure [TACTICS-HF]; NCT01644331).

274 cy department visits for asthma/wheezing and congestive heart failure than PM2.5.

275 ior stroke, hypertension, renal disease, and congestive heart failure than white men but lower rates

276 kg and no history of severe liver disease or congestive heart failure, the final model, which perform

277 Among patients with congestive heart failure, the rate of occurrence of adve

278 For patients with a history of congestive heart failure, the respective rates were 22.8

279 and systemic right ventricles have premature congestive heart failure; there is also a growing concer

280 eing completely asymptomatic; to features of congestive heart failure to vaginal bleeding which may a

281 Congestive heart failure typically arises from cardiac m

282 .0; 95% confidence interval [CI], 4.8-13.5), congestive heart failure (unadjusted HR, 3.2; 95% CI, 1.

283 Current pathophysiological models of congestive heart failure unsatisfactorily explain the de

284 o 2016 for SAVR, TAVR, and disease symptoms (congestive heart failure, unstable angina, non-ST-elevat

285 ospitalisation for valve-related symptoms or congestive heart failure, valve-related dysfunction requ

286 he relative risk of coronary artery disease, congestive heart failure, valvular heart disease, perica

287 s, including hypertension, cardiac fibrosis, congestive heart failure, ventricular remodeling, and di

288 visits with 17alpha(H),21beta(H)-hopane and congestive heart failure visits with elemental carbon.

289 risk score PANWARDS (platelets, albumin, no congestive heart failure, warfarin, age, race, diastolic

290 tio, 11.42 [95% CI, 10.93-11.93]; P < .001); congestive heart failure was a negative correlatefold (o

291 t wave days, but risk of hospitalization for congestive heart failure was lower (P < .05).

292 0.48-1.35; P=0.41), and the reduction of new congestive heart failure was not statistically significa

293 death, documented stroke, and admission for congestive heart failure was recorded.

294 ting of cardiac death, reinfarction, and new congestive heart failure were assessed during long-term

295 schemic attack, prior systemic embolism, and congestive heart failure were associated with more frequ

296 articipants, but not seniors, and those with congestive heart failure were less likely to achieve a 2

297 rdial infarction, stroke, and progression to congestive heart failure were recorded.

298 o prespecified cardiac events or symptomatic congestive heart failures were reported.

299 of 50 dogs (15 healthy dogs and 35 dogs with congestive heart failure) were prospectively recruited,

300 ICA trial (Atrial Fibrillation Management in Congestive Heart Failure With Ablation) did not reveal a

301 on, target vessel revascularization, and new congestive heart failure within 6 months.